

***Fiscal Year 2023 Department of Defense Duchenne Muscular Dystrophy Research Program (DMDRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Idea Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT9425-23-DMDRP-IDA</p>	<p><i>Established Investigators:</i> Independent investigators at or above the level of Assistant Professor (or equivalent); <i>or</i></p> <p><i>New Investigator – Early Stage:</i> Investigators that meet the following criteria by the application submission deadline date:</p> <ul style="list-style-type: none"> • Have not previously received a DMDRP Idea Development Award • Are within 10 years of first faculty appointment (or equivalent) <p><i>New Investigator – Transitioning:</i> Established investigators in an area other than muscular dystrophy at or above the level of Assistant Professor (or equivalent) seeking to transition to a career in Duchenne muscular dystrophy (DMD), thereby bringing their expertise to the field.</p> <p>Must pursue an active line of research in DMD and commit at least 10% of their efforts during each budget year toward the proposed DMD research project.</p>	<ul style="list-style-type: none"> • Supports the development of innovative, high-impact ideas that advance the understanding of DMD and ultimately lead to improved outcomes. • Must address opportunities and challenges in the development of safe and effective macromolecular and cellular therapies that address primary pathology of DMD. Therapies that will be efficacious across the lifespan, including infants, toddlers, and non-ambulatory individuals, are strongly encouraged. • Preliminary data are required. • Clinical trials or applications including a clinical trial aim are not allowed. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$350,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 2 years. 	<p>Pre-Application (Letter of Intent): August 2, 2023 5:00 p.m. ET</p> <p>Application: August 23, 2022 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Translational Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number: HT9425-23-DMDRP-TRA</p>	<p>Investigators at or above the level of Assistant Professor (or equivalent)</p> <p>Early-Career Partnering Principal Investigator (PI) Option:</p> <ul style="list-style-type: none"> The Partnering PI must be an independent, early-career investigator within 10 years of their first faculty appointment (or equivalent) by the time of application submission. Lapses in research time or appointments as denoted in the biographical sketch should be explained in the application. <p>It is encouraged, but not required, that the partnering PI is a clinician or clinical scientist (M.D. or M.D./Ph.D.) to increase collaboration between clinical and non-clinical aspects of DMD research.</p>	<ul style="list-style-type: none"> Supports advanced translational studies that have moved beyond the realm of basic research and proof of concept studies and have the potential to result in a near-term impact in clinical research or the clinic. Research projects investigating therapies that will be efficacious across the lifespan, including infants, toddlers, and non-ambulatory individuals, are strongly encouraged. Preliminary data are required. Clinical trials are allowed. 	<ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is \$1,250,000 for direct costs. Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. The maximum period of performance is 3 years. <p>Early-Career Partnering PI Option:</p> <ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is \$1,350,000 for direct costs. Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): August 2, 2023 5:00 p.m. ET</p> <p>Application: August 23, 2022 11:59 p.m. ET</p>